Literature DB >> 23799547

Rosuvastatin prevents pressure overload‑induced myocardial hypertrophy via inactivation of the Akt, ERK1/2 and GATA4 signaling pathways in rats.

Xue Xu1, Lei Zhang, Jiangjiu Liang.   

Abstract

Pressure overload‑induced myocardial hypertrophy is associated with a poor prognosis in humans and contributes to the development of cardiac arrhythmias, diastolic dysfunction and ultimate congestive heart failure. 3‑Hydroxy‑3‑methylglutaryl‑CoA (HMG‑CoA) reductase inhibitors, also known as statins, have been previously shown to induce regression of myocardial hypertrophy in aortic banding models. However, there is limited knowledge regarding the underlying molecular mechanisms. Therefore, we hypothesized that the myocardial hypertrophy‑related signaling pathways protein kinase B (Akt), extracellular signal‑regulated kinases 1 or 2 (ERK1/2) and GATA binding protein 4 (GATA4) activation pathways constitute targets of rosuvastatin (RSV). Therefore, the above‑mentioned activation pathways were hypothesized to be involved in the regression of pressure overload‑induced myocardial hypertrophy treated by RSV. Twenty‑eight Wistar rats were randomly allocated into 4 groups: the sham operation‑vehicle (SH‑V), abdominal aortic constriction‑vehicle (AAC‑V), abdominal aortic constriction‑RSV 10 mg/kg/day (AAC‑LO) and the abdominal aortic constriction‑RSV 20 mg/kg/day (AAC‑HI) group. Following the establishment of the abdominal aorta constriction model, we investigated the effect of RSV, a new hydrophilic statin, on abdominal aortic constriction‑induced myocardial hypertrophy as well as the underlying intercellular signaling pathways after 5 days and 4 weeks of drug intervention. Moreover, echocardiographic features and the left ventricular weight to final body weight ratio (LVW/BW) were determined. Cross‑sectional areas (CSAs) of cardiomyocytes were assessed by hematoxylin and eosin (H&E) staining. Atrial natriuretic factor (ANF), β‑myosin heavy chain (β‑MHC) and peroxisome proliferator‑activated receptor α (PPARα) messenger RNA (mRNA) expression was assessed using RT‑PCR. The phosphorylation of Akt, ERK1/2 and GATA4 were also examined using western blot analysis. Our results showed that RSV significantly attenuates pressure overload‑induced myocardial hypertrophy by preventing myocardial hypertrophy‑related activation of Akt, ERK1/2 and GATA4 signaling pathways.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23799547     DOI: 10.3892/mmr.2013.1548

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  5 in total

1.  Augmentation of autophagy by atorvastatin via Akt/mTOR pathway in spontaneously hypertensive rats.

Authors:  Wei Wang; Hao Wang; Qing-Xin Geng; Hua-Ting Wang; Wei Miao; Bo Cheng; Di Zhao; Guang-Min Song; Groban Leanne; Zhuo Zhao
Journal:  Hypertens Res       Date:  2015-07-30       Impact factor: 3.872

2.  Salvianolic Acid B Alleviates Heart Failure by Inactivating ERK1/2/GATA4 Signaling Pathway after Pressure Overload in Mice.

Authors:  Juan Yu; Renshan Chen; Yafang Tan; Jiashin Wu; Jianyong Qi; Minzhou Zhang; Weiwang Gu
Journal:  PLoS One       Date:  2016-11-28       Impact factor: 3.240

3.  Mechanisms of Chinese Medicine Xinmailong's protection against heart failure in pressure-overloaded mice and cultured cardiomyocytes.

Authors:  Jianyong Qi; Juan Yu; Yafang Tan; Renshan Chen; Wen Xu; Yanfen Chen; Jun Lu; Qin Liu; Jiashin Wu; Weiwang Gu; Minzhou Zhang
Journal:  Sci Rep       Date:  2017-02-16       Impact factor: 4.379

4.  Protective Mechanisms of Suxiao Jiuxin Pills () on Myocardial Ischemia-Reperfusion Injury in vivo and in vitro.

Authors:  Ya-Fang Tan; Juan Yu; Wen-Jun Pan; Jian-Yong Qi; Min-Zhou Zhang
Journal:  Chin J Integr Med       Date:  2020-06-10       Impact factor: 1.978

5.  Rosuvastatin Reverses Hypertension-Induced Changes in the Aorta Structure and Endothelium-Dependent Relaxation in Rats Through Suppression of Apoptosis and Inflammation.

Authors:  Qingbo Lv; Yao Wang; Ya Li; Liding Zhao; Yingchao Gong; Meihui Wang; Min Wang; Guosheng Fu; Wenbin Zhang
Journal:  J Cardiovasc Pharmacol       Date:  2020-06       Impact factor: 3.271

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.